Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China
PurposePatients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the management of sepsis in Chinese patients with hematological dise...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1613414/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849408042660003840 |
|---|---|
| author | Yan Xie Ziyi Liu Peiqi Liang Dong Wang Qian Li Meng Gao Jindan Kong Depei Wu Jiajun Qi Jie Xu Jianhong Fu |
| author_facet | Yan Xie Ziyi Liu Peiqi Liang Dong Wang Qian Li Meng Gao Jindan Kong Depei Wu Jiajun Qi Jie Xu Jianhong Fu |
| author_sort | Yan Xie |
| collection | DOAJ |
| description | PurposePatients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the management of sepsis in Chinese patients with hematological diseases.MethodsA retrospective study was conducted on hematological diseases patients diagnosed as sepsis and treated with CMS at the First Affiliated Hospital of Soochow University between November 2021 and July 2023. Demographics, clinical presentation, causative organisms, clinical outcomes and adverse events (AEs) were recorded. The univariate and multivariate analysis was conducted to identify predictive factors for clinical effectiveness and renal insufficiency.ResultsA total of 81 hematological patients diagnosed with sepsis were included, the mean (change in sequential organ failure assessment [SOFA] score) ΔSOFA when utilizing CMS was 3.90 ± 2.10. Following CMS treatment, a clinical effectiveness rate was observed in 62.96% of patients, while the bacteriological eradication rate was 60.23%. Additionally, the 28-day all-cause mortality rate was 29.63%. The median length of stay in the ICU and total in-hospital stay was 13.5 and 33 days, respectively. AEs were reported in 16 patients (19.75%), including 15 (18.52%) renal insufficiency, 1 (1.23%) hepatic insufficiency, and 1 (1.23%) rash. The multivariate analysis of clinical effectiveness indicated that a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score, a higher Charlson comorbidity index, the relapse or refractory of hematological diseases, septic shock, and the use of mechanical ventilation was independently associated with a poor clinical effectiveness. The univariate analysis of renal insufficiency demonstrated that allogeneic hematopoietic stem cell transplantation, aplastic anemia, and gastrointestinal infection had a statistically significant impact on renal function.ConclusionsThe findings of our study demonstrated that CMS was an efficacious treatment for sepsis in Chinese patients with hematological diseases, while concurrently exhibiting an acceptable toxicity profile. |
| format | Article |
| id | doaj-art-5ba19933deba4f4dae96896d8a6a9ba6 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-5ba19933deba4f4dae96896d8a6a9ba62025-08-20T03:35:53ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-08-011510.3389/fcimb.2025.16134141613414Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in ChinaYan Xie0Ziyi Liu1Peiqi Liang2Dong Wang3Qian Li4Meng Gao5Jindan Kong6Depei Wu7Jiajun Qi8Jie Xu9Jianhong Fu10Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaDepartment of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaDepartment of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaDepartment of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaDepartment of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaDepartment of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaIntensive Care Medicine Department, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaEducation Training Center, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaCenter of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases (Suzhou), Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu, ChinaPurposePatients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the management of sepsis in Chinese patients with hematological diseases.MethodsA retrospective study was conducted on hematological diseases patients diagnosed as sepsis and treated with CMS at the First Affiliated Hospital of Soochow University between November 2021 and July 2023. Demographics, clinical presentation, causative organisms, clinical outcomes and adverse events (AEs) were recorded. The univariate and multivariate analysis was conducted to identify predictive factors for clinical effectiveness and renal insufficiency.ResultsA total of 81 hematological patients diagnosed with sepsis were included, the mean (change in sequential organ failure assessment [SOFA] score) ΔSOFA when utilizing CMS was 3.90 ± 2.10. Following CMS treatment, a clinical effectiveness rate was observed in 62.96% of patients, while the bacteriological eradication rate was 60.23%. Additionally, the 28-day all-cause mortality rate was 29.63%. The median length of stay in the ICU and total in-hospital stay was 13.5 and 33 days, respectively. AEs were reported in 16 patients (19.75%), including 15 (18.52%) renal insufficiency, 1 (1.23%) hepatic insufficiency, and 1 (1.23%) rash. The multivariate analysis of clinical effectiveness indicated that a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score, a higher Charlson comorbidity index, the relapse or refractory of hematological diseases, septic shock, and the use of mechanical ventilation was independently associated with a poor clinical effectiveness. The univariate analysis of renal insufficiency demonstrated that allogeneic hematopoietic stem cell transplantation, aplastic anemia, and gastrointestinal infection had a statistically significant impact on renal function.ConclusionsThe findings of our study demonstrated that CMS was an efficacious treatment for sepsis in Chinese patients with hematological diseases, while concurrently exhibiting an acceptable toxicity profile.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1613414/fullcolistimethate sodiumhematological diseases patientssepsiseffectivenesssafety |
| spellingShingle | Yan Xie Ziyi Liu Peiqi Liang Dong Wang Qian Li Meng Gao Jindan Kong Depei Wu Jiajun Qi Jie Xu Jianhong Fu Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China Frontiers in Cellular and Infection Microbiology colistimethate sodium hematological diseases patients sepsis effectiveness safety |
| title | Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China |
| title_full | Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China |
| title_fullStr | Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China |
| title_full_unstemmed | Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China |
| title_short | Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China |
| title_sort | colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients a retrospective study in china |
| topic | colistimethate sodium hematological diseases patients sepsis effectiveness safety |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1613414/full |
| work_keys_str_mv | AT yanxie colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT ziyiliu colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT peiqiliang colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT dongwang colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT qianli colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT menggao colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT jindankong colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT depeiwu colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT jiajunqi colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT jiexu colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina AT jianhongfu colistimethatesodiumisefficaciousandsafeforthemanagementofsepsisinhematologicaldiseasespatientsaretrospectivestudyinchina |